Is the ebola virus curable

In this case, the body needs oxygen. Replace lost blood. If there is internal bleeding in severe cases, there should be a replacement for the lost blood. Failure to do so can even lead to death. Other infections There are many other infections associated with Ebola virus fever. Many people have multiple infections with this fever. There is no specific treatment for this virus, at least other infections can be treated with medication.

Helps reduce complications to some extent. Better safety Another way to treat this virus is to strengthen the immune system. A person with the virus must have plenty of water and fluid in their body. A balanced diet is also needed to strengthen the immune system. A good immune system always helps to fight any virus. Apply for a Grant. After You Submit an Application. Manage Your Award.

Funding News. NIAID is conducting and funding research on several experimental Ebola treatments, with the goal of alleviating suffering and stopping the spread of disease. It was designed to compare mortality among patients receiving one of three investigational drugs mAb, REGN-EB3 and remdesivir with a control group of patients receiving the investigational monoclonal antibody cocktail treatment ZMapp.

The results prompted an independent data and safety monitoring board to recommend the study be stopped and that all future patients be randomized to receive REGN-EB3 or mAb in an extension phase of the study. VRC initially developed and manufactured the mAb antibody product, which has now been licensed to Ridgeback Biotherapeutics for advanced development. This prevents the virus from entering and infecting cells. A single dose of mAb fully protects non-human primates five days after lethal Ebola virus infection, and results from a Phase 1 clinical trial of mAb indicated the investigational treatment is safe.

NIAID supported the early development and preclinical testing of ZMapp, a "cocktail" of three different monoclonal antibodies. The antibodies bind to three different regions of the glycoprotein of the Ebola virus, inhibiting viral replication. During initial experiments, the antibodies were produced in tobacco plants specifically bioengineered to produce large quantities of the proteins.

They can also be produced in a cell line derived from hamster ovaries known as CHO cells. ZMapp was administered under emergency use authorization to Ebola-infected patients during the outbreak. Results indicate the antibody cocktail was well-tolerated and showed promise, but there was insufficient data to determine definitively whether it is a better treatment for Ebola virus disease than supportive care alone.

The investigational antiviral agent GS, also known as remdesivir, is being developed by Gilead as a treatment for Ebola virus disease. Remdesivir is no longer being administered to patients with Ebola virus disease in the DRC after the preliminary results of the PALM trial were announced. However, the antiviral is being considered for combination therapy, which would need to be explored in preclinical studies first.

BCX also known as galidesivir developed by BioCryst Pharmaceuticals with support from NIAID, is an investigational small molecule drug with broad spectrum antiviral activity, including against Ebola. Skip to main content. Skip to Back. Search for Resources.

Division of Intramural Research Labs. Research at Vaccine Research Center. Clinical Research. Infectious Diseases. Resources for Researchers. Managing Symptoms. Understanding Triggers. Autoimmune Diseases. Inmazeb was evaluated in adult and pediatric patients with confirmed Zaire ebolavirus infection in one clinical trial the PALM trial and as part of an expanded access program conducted in the Democratic Republic of the Congo DRC during an Ebola virus outbreak in In the PALM trial, the safety and efficacy of Inmazeb was evaluated in a multi-center, open-label, randomized controlled trial, in which patients received Inmazeb 50 mg of each monoclonal antibody intravenously as a single infusion, and patients received an investigational control.

The primary efficacy endpoint was day mortality. The primary analysis population was all patients who were randomized and concurrently eligible to receive either Inmazeb or the investigational control during the same time period of the trial. Of the patients who received Inmazeb, In the expanded access program, an additional patients received Inmazeb.

But it takes many years of painstaking reverse-engineering to make them. Zmapp, for instance, was developed by infecting mice with Ebola and then collecting the antibodies the mice produced against the virus. Those antibodies then had to be further engineered to look more like a human antibody, so as not to provoke an immune reaction. But compared with other viruses, Ebola is large and has the ability to change shape, making it difficult for any one antibody to block its infection.

An even better solution, some have posited , would be to mine the serum of Ebola survivors and harvest the DNA from the white blood cells that make antibodies.